PMID- 21929284
OWN - NLM
STAT- MEDLINE
DCOM- 20120823
LR  - 20190116
IS  - 1029-2403 (Electronic)
IS  - 1026-8022 (Linking)
VI  - 53
IP  - 4
DP  - 2012 Apr
TI  - Double high-dose therapy with dose-intensive cyclophosphamide, etoposide, 
      cisplatin (DICEP) followed by high-dose melphalan and autologous stem cell 
      transplantation for relapsed/refractory Hodgkin lymphoma.
PG  - 596-602
LID - 10.3109/10428194.2011.624227 [doi]
AB  - The purpose of the present study was to review retrospectively our results of 
      double high-dose therapy with DICEP (dose-intensified cyclophosphamide 5.25 
      g/m(2), etoposide 1.05 g/m(2), and cisplatin 105 mg/m(2)) re-induction followed 
      by high dose melphalan 200 mg/m(2) (HDM) and autologous stem cell transplantation 
      (ASCT) for 73 consecutive patients with relapsed (n = 43) or refractory (n = 30) 
      classical Hodgkin lymphoma (HL) treated between June 1995 and November 2009. 
      DICEP chemotherapy resulted in successful stem cell mobilization in 71 patients 
      (97%), with a median CD34 (+) cell collection of 15.6 x 10(6)/kg. With a median 
      follow-up of 56 months post-DICEP, the 5-year progression free survival (PFS) and 
      overall survival (OS) rates were 61% [95%CI = 49-72%] and 80% [95%CI = 69-89%], 
      respectively. The 5-year PFS was 65% vs. 30% for DICEP responders vs. 
      nonresponders (logrank p = 0.003) and 89% for International Prognostic Score 
      (IPS) = 0-1, 56% for IPS = 2-3, and 24% for IPS = 4-7 (logrank p < 0.001). 
      Response to DICEP and IPS at relapse were the only two factors that independently 
      predicted PFS and OS in multivariate analyses. Treatment-related mortality was 
      1%. In conclusion, DICEP-HDM/ASCT is well tolerated double high-dose therapy 
      associated with excellent stem cell mobilization and favorable PFS and OS 
      outcomes for relapsed as well as primary refractory HL.
FAU - Shafey, Mona
AU  - Shafey M
AD  - Department of Oncology, Tom Baker Cancer Centre and University of Calgary, 
      Calgary, AB, Canada. mona.shafey@albertahealthservices.ca
FAU - Duan, Qiuli
AU  - Duan Q
FAU - Russell, James
AU  - Russell J
FAU - Duggan, Peter
AU  - Duggan P
FAU - Balogh, Alex
AU  - Balogh A
FAU - Stewart, Douglas A
AU  - Stewart DA
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 6PLQ3CP4P3 (Etoposide)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - Q20Q21Q62J (Cisplatin)
RN  - Q41OR9510P (Melphalan)
SB  - IM
MH  - Adult
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Cisplatin/administration & dosage
MH  - Combined Modality Therapy
MH  - Cyclophosphamide/administration & dosage
MH  - Disease-Free Survival
MH  - Dose-Response Relationship, Drug
MH  - Drug Administration Schedule
MH  - Etoposide/administration & dosage
MH  - Female
MH  - Follow-Up Studies
MH  - Hematopoietic Stem Cell Transplantation/*methods
MH  - Hodgkin Disease/*drug therapy/pathology/*surgery
MH  - Humans
MH  - Male
MH  - Melphalan/administration & dosage
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Recurrence
MH  - Retrospective Studies
MH  - Salvage Therapy
MH  - Transplantation, Autologous
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2011/09/21 06:00
MHDA- 2012/08/24 06:00
CRDT- 2011/09/21 06:00
PHST- 2011/09/21 06:00 [entrez]
PHST- 2011/09/21 06:00 [pubmed]
PHST- 2012/08/24 06:00 [medline]
AID - 10.3109/10428194.2011.624227 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2012 Apr;53(4):596-602. doi: 10.3109/10428194.2011.624227.